Navigation Links
Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms

At two years, Company's TAXUS(R) and PROMUS(TM) Stents demonstrate positive

and similar outcomes

NATICK, Mass. and CHICAGO, March 31 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed positive two-year results from Abbott's prospective, randomized (3:1), single blind, non-inferiority SPIRIT II Trial comparing the safety and efficacy of the XIENCE(TM) V (PROMUS(TM)) Everolimus-Eluting Coronary Stent and Boston Scientific's worldwide market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System ("TAXUS Stent") in 300 patients in Europe. The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. Boston Scientific is the only company offering two distinct drugs on two deliverable platforms - the TAXUS and PROMUS Stents. The results were presented today at the SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago by Professor Patrick Serruys, M.D., Ph.D., Chief of Interventional Cardiology, Thoraxcenter-Erasmus University Rotterdam, The Netherlands, and the SPIRIT II Principal Investigator.

At two years, results from the SPIRIT II trial demonstrated no numerical difference between the XIENCE V (PROMUS) Stent and the TAXUS Stent in their angiographic outcomes, nor were there statistically significant differences in the clinical outcomes. The cardiac death rate for the XIENCE V (PROMUS) Stent was 0.5 percent and for the TAXUS Stent was 1.4 percent (p=0.45). Myocardial infarction (MI) rates for the XIENCE V (PROMUS) Stent and the TAXUS Stent were 2.8 percent and 5.5 percent (p=0.29), respectively. Ischemia-driven target lesion revascularization (ID-TLR) rates were comparable, at 3.8 percent for the XIENCE V (PROMUS) Stent and 6.8 percent for the TAXUS Stent (p=0.33). Major adverse cardiac events (MACE) rates comprised of cardiac death, all MI and ID-TLR were also comparable, at 6.6 percent for the XIENCE V (PROMUS) Stent and 11.0 percent for the TAXUS Stent (p=0.31).

Stent thrombosis rates at two years using the Academic Research Consortium (ARC) definite/probable definition were low for both the XIENCE V (PROMUS) Stent (0.9%) and the TAXUS Stent (1.4%). Angiographic outcomes showed numerically equivalent late loss, with 0.33 mm for XIENCE V (PROMUS) and 0.34 mm for TAXUS (p=0.60). In-stent binary restenosis rates at two years were also comparable for the XIENCE V (PROMUS) Stent and the TAXUS Stent (2.1% vs. 2.9%, p=1.0).

"Boston Scientific's two DES platforms - the TAXUS and PROMUS Stents - both performed extremely well in the SPIRIT II Trial out to two years," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "The data, once again, demonstrated impressive safety and efficacy profiles with low stent thrombosis rates and similar clinical outcomes. We look forward to future data from the SPIRIT Clinical Trial Program as well as from our PROENCY Registries in Europe and the United States - the first to observe different 'Olimus-eluting coronary stents in a real-world setting."

In February, Boston Scientific announced that the first patient had been enrolled in its PROENCY (PROMUS(TM), ENdeavor(R) and CYpher(R)) European Registry. The registry will collect real-life clinical outcome data for the PROMUS Stent and compare them with data from Johnson & Johnson's Cypher(R) Sirolimus-Eluting Stent and Medtronic's Endeavor(R) Zotarolimus-Eluting Stent in patients in routine clinical practice. A U.S. PROENCY Registry is expected to begin enrolling patients in July and complete enrollment by the end of 2008.

The XIENCE(TM) V (PROMUS) Stent is currently pending approval by the U.S. Food and Drug Administration (FDA), which is expected to occur in the first half of 2008. Upon FDA approval of the PROMUS Stent, Boston Scientific will immediately make it available for sale in the United States.

The PROMUS Stent is an investigational device in the U.S. and not yet approved for sale. The PROMUS Stent is currently for sale in Europe and certain other international markets. TAXUS and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of the Abbott Laboratories group of companies. The SPIRIT Clinical Program is sponsored by Abbott.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, product performance, competitive offerings, procedural volume, overall market size and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
3. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
4. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
9. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
10. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
11. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
Post Your Comments:
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
(Date:11/25/2015)... SYDNEY , Nov. 26, 2015  The total global ... nearly 7% over 2015-2016. Latin America ... Asia , (excluding Japan ), is ... continues to face increased healthcare expenditure. In 2013-2014, ... expenditure declined from 43.5% in 2008-2009 to 41.2% in 2013-2014. ...
(Date:11/25/2015)... , Nov. 25, 2015 On Tuesday, ... federal bellwether trial against Wright Medical Technology, Inc. ... their Conserve metal-on-metal hip implant device, awarded $11 ... a two week trial and three days of ... hip device was defectively designed and unreasonably dangerous, ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... According to ... out by the University of Toronto and the University of British Columbia suggested that ... for head injuries. The article explains that part of the reason for the controversial ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at ... people age, more care is needed, especially with Alzheimer’s, dementia and other cognitive ... being overworked. The forgotten part of this equation: 80 percent of medical care ...
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, ... to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. ... dispense prescription medications. In doing so, it could help to prevent potential overdose ...
(Date:11/27/2015)... ... , ... Lizzie’s Lice Pickers just announced a special promotion that will run ... purchase of lice treatment product. In addition, customers will receive a complimentary head Check ... lice is a sure way to ruin the holidays, so we encourage all of ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a set of ... With ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease ...
Breaking Medicine News(10 mins):